Analgesic system (Sevoflurane, Propofol, and Remifentanil combination)

The "Analgesic system – sevoflurane + propofol + remifentanil combination" is not a single molecular target but rather a pharmacological protocol used in balanced anesthesia (StatPearls, 2023). This regimen combines an inhaled volatile anesthetic (sevoflurane), an intravenous sedative-hypnotic (propofol), and an ultra-short-acting opioid (remifentanil) to achieve the primary goals of general anesthesia: unconsciousness, analgesia, and attenuation of autonomic reflexes (Miller's Anesthesia, 2020). Sevoflurane and propofol primarily target the GABA-A receptor complex to facilitate inhibitory neurotransmission, while remifentanil selectively activates mu-opioid receptors in the central nervous system to block pain signaling (PubChem, 2024). By targeting multiple pathways simultaneously, this combination allows for a reduction in the required dose of each individual component, thereby potentially improving the safety profile and recovery time for patients undergoing surgical procedures (PubMed, PMID: 11591214). However, the use of this system requires careful monitoring of hemodynamic and respiratory parameters due to the potent depressant effects of the constituent drugs. It is frequently employed in complex surgeries where rapid titration of anesthetic depth and immediate emergence are desired. This approach leverages the synergistic interactions between different classes of drugs to optimize the anesthetic state while minimizing side effects like nausea or prolonged sedation (NCBI, 2023).

Other names

Balanced anesthesia protocolSevoflurane-Propofol-Remifentanil regimenCombined intravenous-inhalational anesthesia

This combination utilizes a multi-modal approach to anesthesia. Propofol and sevoflurane primarily act as positive allosteric modulators of the GABA-A receptor to induce hypnosis and sedation, while sevoflurane also inhibits NMDA receptors and activates glycine receptors (StatPearls, 2023). Remifentanil acts as a potent, short-acting agonist at the mu-opioid receptor to provide intense analgesia (NCBI, 2023). Together, they produce a synergistic effect that allows for lower doses of each agent, reducing individual toxicity while maintaining a deep anesthetic state (Anesthesia & Analgesia, 2001).